Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLDN6/GPC3/Mesothelin/AXL-CAR-NK in Advanced Solid Tumors
NCT05410717Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2022
- Primary completion
- Jun 2030
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of claudin 6 chimeric antigen receptor natural killer cell + glypican 3 chimeric antigen receptor natural killer cell + mesothelin chimeric antigen receptor natural killer cell + axl chimeric antigen receptor natural killer cell in solid tumor, ovarian cancer, testicular cancer and 1 more (5 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0 up to 52 weeks. Started Jun 2022; status: recruiting.
02
Drugs
claudin 6 chimeric antigen receptor natural killer cell + glypican 3 chimeric antigen receptor natural killer cell + mesothelin chimeric antigen receptor natural killer cell + axl chimeric antigen receptor natural killer cell
03
Conditions
solid tumorovarian cancertesticular cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT05410717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410717.